TSLA
Tesla
-- 248.710 NVDA
NVIDIA
-- 117.700 PLTR
Palantir
-- 90.960 MU
Micron Technology
-- 94.720 AAPL
Apple
-- 218.270 
NEWS
NMPA Grants Marketing Approval to the First Co-Developed NGS-Based Companion Diagnostic for Lung Cancer in China
Burning Rock Biotech (NASDAQ: BNR) and Dizal have jointly announced the approval of the first co-developed NGS-based companion diagnostic (CDx) for lung cancer by China's National Medical Products Administration (NMPA). This CDx is designed for EGFR exon 20 insertion mutation (exon20ins) for sunvozertinib, marking a significant milestone in precision oncology.
The approval is the result of simultaneous development of Burning Rock's LungCure CDx and Dizal's sunvozertinib therapy, offering an innovative precision treatment solution for non-small cell lung cancer patients with EGFR exon20ins.
This collaboration sets a new benchmark for concurrent development of companion diagnostics for anti-tumor drugs and positions Burning Rock to drive global CDx development for pharmaceutical companies.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment